China Firm Gets First U.S. Approval To Begin TCM Clinical Trials
This article was originally published in PharmAsia News
Executive Summary
A traditional Chinese medicine has received U.S. clearance to begin clinical trials on the way to possible FDA approval as a marketable drug in the country. The Shanghai University of Traditional Chinese Medicine developed the medicine capsule it calls Fuzheng Huayu. The medicine relies on a compound of six herbs to treat hepatitis C patients who have developed fibrosis of the liver. If approved by U.S. FDA, it would be the first TCM from China to receive clearance. (Click here for more